<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    How did Takeda's revenue and expenses trend in Q1 2025 compared to previous quarters?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 11:36pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Takeda Pharmaceutical's revenue and expenses for Q1 2025 are not currently available. However, the latest available data is from the previous quarter ending on March 31, 2024, with total revenue reported at $28.2 billion and total expenses not provided.


</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae){return {layout:"default",data:[{noData:c,currentQuestion:e,textDescription:F,comeFrom:"AInvestShareLink",events:[],answerSource:j}],fetch:{},error:k,state:{sharePreviewModule:{loadJgySuccess:f,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:l,agent_id:a,output_media_info:[],task_id:a,language:a,source:j,cache_builder:a,reply_action:"Answer",execute_mode:y,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"How did Takeda's revenue and expenses trend in Q1 2025 compared to previous quarters?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"How did Takeda's revenue and expenses trend in Q1 2025 compared to previous quarters?\",\"user_id\":\"dp87324150\",\"user_name\":\"\",\"trace_id\":\"e90f16a3-bf66-4c0e-bdb7-6de94efa60e7\",\"session_id\":\"e90f16a3-bf66-4c0e-bdb7-6de94efa60e7\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"query_data",query_type:z,text:"4 results found:\n|stock code|stock name|Last Price|Last Change|Total Revenue (Cum)|Total Expenses (Cum)|Report End Date|\n|---|---|---|---|---|---|---|\n|TAK|Takeda Pharmaceutical|$14.28|-5.21%|$28.2 billion||20240331|\n|TAK|Takeda Pharmaceutical|$14.28|-5.21%|$22.42 billion||20241231|\n|TAK|Takeda Pharmaceutical|$14.28|-5.21%|$16.64 billion||20240930|\n|TAK|Takeda Pharmaceutical|$14.28|-5.21%|$7.51 billion||20240630|\n",query_data:{number:l,title:A,query_type:z,condition:a,model_sql:G,data_ext_params:{merge_repeat:c,expand_index:b,data_add:l,add_index:f}}}],answer_chain_name:H,agent_mode:I,native_answer:a,come_from:a,text_answer:F,trace_id:g,cost:15252,event_names:a,question:e,fallback_type:J,input_type:K,fall_back_reason:{fall_back_type:J,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:g,first_return_cost:3401,cache_type:"no_cache",question_id:g,transfer_question:e,signal_type:"ON_COMPLETE",start_time:B,remote_svc:j,slots:[],answer_type:y,user_id:r,skill_name:C},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:g,session_id:g,user_id:r,question:e,source:j,raw_question:e,version:"3.4.1",action_name:C,nlu:{entity:[{type:L,value:"TAK.N",market:M}]},output_time:B,deep_research:c,deep_thinking:c,agent_mode:I},extra:{}},{answer_path:s,section:{id:t,info_texts:["Thinking"],show_type:u,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:s,section:{id:t,info_texts:["Querying Stock: TAK Revenue (FY), Expenses (FY) in the past four quarters"],show_type:u,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"thinking"},logs:[],extra:{action:"Querying Stock",action_input:A,thought:"The user wants to compare Takeda's Q1 2025 revenue and expenses with previous quarters. I should focus on Takeda's quarterly revenue and expense data for the past four quarters. I will use FinQuery for the data."}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:s,section:{id:t,info_texts:["Generating Answer"],show_type:u,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:d,section:{id:v,info_texts:[],show_type:w,voice_txt:"T",text_answer:N,rich_text:N,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:2000,info_texts:[],show_type:w,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:A,query_type:z,trace_data:a,index:l,model_sql:G,data_ext_params:{merge_repeat:c,expand_index:b,data_add:l,add_index:f},jump_type:"data_query"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:m,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:v,info_texts:[],show_type:w,voice_txt:".\n\n",text_answer:O,rich_text:O,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"TAK",market_id:M,name:P,domain:L},pos:f,section_id:v,txt:P,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:v,info_texts:[],show_type:w,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:s,section:{id:t,info_texts:["Completed"],show_type:u,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"afb20c6e0d05188431af7a08631dc23c",item_type:i,item_name:n,rec_info:Q}},{display_text:o,query_text:o,trace_info:{item_id:"46bf8704f6b4df704619e44867106b28",item_type:i,item_name:o,rec_info:R}},{display_text:p,query_text:p,trace_info:{item_id:"da33d19e77ebd5d4679096edac8a18c2",item_type:i,item_name:p,rec_info:S}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:f,type:"1",display2:c,url:a}},request_config:[{source_type:T,related_name:U}],puuid:D,tag:a,category:"custom",uuid:V}],global:{urp_static_data:[{name:U,value:{status_code:f,columns:[{type:q,index_name:W,key:W},{type:q,index_name:X,key:X},{type:q,index_name:Y,key:Y},{type:q,index_name:Z,key:Z},{type:q,index_name:_,key:_}],datas:[{send_text:n,item_type:i,rec_info:Q,display_text:n,rec_reason:a},{send_text:o,item_type:i,rec_info:R,display_text:o,rec_reason:a},{send_text:p,item_type:i,rec_info:S,display_text:p,rec_reason:a}],dataSize:T,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:$,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:x,"min-height":"100%",position:aa,height:x},isMaterial:c,id:$,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:f,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:E,componentUuid:V,script:[{name:ab,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:E,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:E},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:x,position:aa,height:x},isMaterial:b,_id:19,id:ab,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:ac,voice_txt:a,tracking_info:{},uuid:D},order:{is_auto:c,render_for:ac,chart_type:"command",puuid:D}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:C,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:y,answer_chain_name:H},is_deep_research:c,deep_thinking:c,create_time:1746718576044},is_last:b}],questionItem:{data:{qStr:e,encodeFlag:c,imageData:k,docsData:[],quoteData:k},tplType:"question"},events:ad,agentId:a,param:{entity_info:{},add_info:{ori_question:e},event_list:ad,client_ip:a,question:e,user_id:r,user_name:a,trace_id:g,session_id:g,source:j,input_type:K}}],userId:r,userName:a,startTime:B,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:k,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:f,traceTableData:k,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fhow-did-takedas-revenue-and-expenses-trend-in-q1-2025-compared-to-previous-quarters-ffde40\u002F",config:{_app:{basePath:ae,assetsPath:ae,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"other\u002FopenAnswer","How did Takeda's revenue and expenses trend in Q1 2025 compared to previous quarters?",0,"e90f16a3-bf66-4c0e-bdb7-6de94efa60e7","signal","llm_generated","ths_ainvest_lite_web",null,1,999,"What was Takeda's net income in Q1 2025?","How did Takeda's operating expenses change in Q1 2025?","What were Takeda's key revenue sources in Q1 2025?","STR","dp87324150","progress\u002Fsearching_for",1000,"searching_for",2001,"rich_text","auto","agent","intusstock","TAK Revenue (FY), Expenses (FY) in the past four quarters",1746718560792,"inspect stocks","39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Takeda Pharmaceutical's revenue and expenses for Q1 2025 are not currently available. However, the latest available data is from the previous quarter ending on March 31, 2024, with total revenue reported at $28.2 billion and total expenses not provided.\n\n\n","select   stock_code,   total_revenue_cum,   total_expenses_cum from   ustock_fin_data where   report_end_date = recent ('4q')   and stock_code = 'TAK.N'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","169","Takeda Pharmaceutical's revenue and expenses for Q1 2025 are not currently available. However, the latest available data is from the previous quarter ending on March 31, 2024, with total revenue reported at $28.2 billion and total expenses not provided[^1]",".\n\n\n``` visual\n{\"uuid\":\"f8987fed-7f64-4be3-8b83-ec57a4c0aeeb\"}\n```","Takeda Pharmaceutical","2+679_496_21_554+0+0+e90f16a3-bf66-4c0e-bdb7-6de94efa60e7+afb20c6e0d05188431af7a08631dc23c+llm_generated+aimeTagAnalysis+0+0.005779446102678776+1","2+679_496_21_554+0+0+e90f16a3-bf66-4c0e-bdb7-6de94efa60e7+46bf8704f6b4df704619e44867106b28+llm_generated+aimeTagAnalysis+0+0.0029590351041406393+2","2+679_496_21_554+0+0+e90f16a3-bf66-4c0e-bdb7-6de94efa60e7+da33d19e77ebd5d4679096edac8a18c2+llm_generated+aimeTagAnalysis+0+0.0027800947427749634+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>